Perkütan Sol Atriyal Apendiks Kapama Sonrası Antitrombotik Tedavi

Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014; 129: 837–847. doi:10.1161/CIRCULATIONAHA.113.005119.

Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22: 983–988. doi: 10.1161/01.str.22.8.983.

J. Katic and J. A. Borovac. Treatment of persistent left atrial appendage thrombus in patients with atrial fibrillation on ade quate oral anticoagulation: pathways of care for all-comers and heart failure patients. Cardiac Failure Review. 2023 Apr 15:9:e05. doi:10.15420/cfr.2022.28.

Reddy VY, Doshi SK, Kar S, et al; PREVAIL and PROTECT AF Investigators. 5-year outcomes after left atrial appendage closure. J Am Coll Cardiol. 2017;70:2964–2975. doi: 10.1016/j.jacc.2017.10.021

Patti G, Pengo V, Marcucci R, et al. The left atrial appendage: from embryology to prevention of thromboembolism.European Heart Journal. 2017; 38: 877–887. doi:10.1093/eurheartj/ehw159.

Galea R, R€ aber L. Antithrombotic therapy after percutaneous left atrial appendage closure: evidence, challenges and future directions. Rev Cardiovasc Med. 2023;24:343. doi:10.31083/j.rcm2412343.

Holmes DR Jr, Korsholm K, Rodes Cabau J, et al. Left atrial appendage occlusion. Euro Intervention. 2023;18:e1038–e1065. doi:10.4244/EIJ-D-22-00627.

Saw J, Holmes DR,Cavalcante JL, et al. SCAI/HR Sex pert consensus statement on transcatheter left atrial appendage closure. JACC Cardiovasc Interv. 2023; 16:1384–1400. doi:10.1016/j.jcin.2023.01.011.

H. Ben, M. Changsheng, W. Shulin. 2019 Chinese expert consensus statement on left atrial appendage closure in patients with atrial fibrillation. Pacing and Clinical Electrophysiology. 2022 Apr;45(4):535-555. doi:10.1111/pace.14448.

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955–962. doi: 10.1016/s0140-6736(13)62343-0.

Della Rocca DG, Magnocavallo M, Di Biase L, et al. Half-dose direct oral anticoagulation versus standard antithrombotic therapy after left atrial appendage occlusion. JACC Cardiovasc Interv. 2021;14:2353–2364. doi: 10.1016/j.jcin.2021.07.031.

Asmarats L, O’Hara G, Champagne J, et al. Short-Term Oral Anticoagulation Versus Antiplatelet Therapy Following Transcatheter Left Atrial Appendage Closure. Circulation. Cardiovascular Interventions. 2020; 13: e009039. doi:10.1161/CIRCINTERVENTIONS.120.009039.

Faroux L, Cruz-González I, Arzamendi D, et al. Short-term direct oral anticoagulation or dual antiplatelet therapy following left atrial appendage closure in patients with relative contraindications to chronic anticoagulation therapy. Int J Cardiol. 2021;333:77–82. doi: 10.1016/j.ijcard.2021.02.054.

Duthoit G, Silvain J, Marijon E, et al. Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Ran domized Pilot Study. Circulation. Cardiovascular Interventions. 2020; 13: e008481. doi: 10.1161/CIRCINTERVENTIONS.119.008481.

Dentali F, Douketis JD, Lim W, et al. Combinedaspirin oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Archives of Internal Medicine. 2007; 167: 117–124. doi:10.1001/archinte.167.2.117.

Pouru JP, Lund J, Jaakkola S, et al. Percutaneous left atrial appendage closure in patients with prior intracranial bleeding and thromboembolism. Heart Rhythm. 2020; 17: 915–921. doi:10.1016/j.hrthm.2020.01.028.

Nielsen-Kudsk JE, Johnsen SP, Wester P, et al. Left atrial appendage occlusion versus standard medical care in patientswith atrial fibrillation and intracerebral haemorrhage: a propensity score-matched follow-up study. EuroIntervention. 2017; 13:371–378. doi:10.4244/EIJ-D-17-00201.

Korsholm K, Nielsen KM, Jensen JM, et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy. EuroIntervention. 2017; 12: 2075–2082. doi:10.4244/EIJ-D-16-00726.

Patti G, Sticchi A, Verolino G, et al. Safety and Efficacy of Single Versus Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion. The American Journal of Cardiology. 2020; 134: 83–90. doi:10.1016/j.amjcard.2020.08.013.

Boersma LVA, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMANdevice: peri-procedural outcomes from the EWOLUTION registry. European Heart Journal. 2016; 37: 2465–2474. doi:10.1093/eurheartj/ehv730.

Landmesser U, Schmidt B, Nielsen-Kudsk JE, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. EuroIntervention. 2017; 13: 867–876. doi:10.4244/EIJ-D-17-00493.

Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update. EP Eur. 2020;22:184–184. doi: 10.4244/EIJY19M08_01.

Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer amulet left atrial appendage occluder versus watchman device for stroke prophylaxis (amulet IDE): a randomized, controlled trial. Circulation. 2021;144:1543 1552. doi: 10.1161/CIRCULATIONAHA.121.057063.

Hildick-Smith D, Landmesser U, Camm AJ, et al. Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. European Heart Journal. 2020; 41: 2894–2901. doi:10.1093/eurheartj/ehaa169.

Søndergaard L, Wong Y-H, Reddy VY, et al. Propensity-matched comparison of oral anticoagulation versus antiplatelet therapy after left atrial appendage closure with WATCHMAN. JACC Cardiovasc Interv. 2019;12:1055–1063. doi: 10.1016/j.jcin.2019.04.004.

Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374: 534–542. doi:10.1016/S0140-6736(09)61343-X.

Holmes DR Jr, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. Journal of the American College of Cardiology. 2014; 64: 1–12. doi:10.1016/j.jacc.2014.04.029.

Galea R, Mahmoudi K, Gräni C, et al. Watchman FLX vs. Watchman 2.5 in a Dual-Center Left Atrial Appendage Closure Cohort: the WATCH-DUAL study. Europace. 2022; 24: 1441–1450. doi:10.1093/europace/euac021.

Lakkireddy DTD,Thaler D, Ellis CR, et al. 3-Year Outcomes from the Am platzer™ Amulet™ Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE). JACC.Cardiovascular Interventions.2023 Aug 14;16(15):1902-1913. doi:10.1016/j.jcin.2023.06.022.

Kar S, Doshi SK, Sadhu A, et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial. Circulation. 2021; 143: 1754–1762. doi:10.1161/CIRCULATIONAHA.120.050117.

Fu G, Wang B, He B, et al. Safety and efficacy of low-dose non-vitamin K antagonist oral anticoagulants versus warfarin after left atrial appendage closure with the Watchman device. Journal of the Formosan Medical Association. 2022; 121: 1488–1494. doi:10.1016/j.jfma.2021.10.015.

Enomoto Y,Gadiyaram VK,Gianni C, et al.Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the Watchman device. Heart Rhythm. 2017; 14: 19–24. doi:10.1016/j.hrthm.2016.10.020.